The focus of traditional treatments on the symptoms rather than the condition has unfortunately made neuropathy a ...

This is the 2nd orphan drug designation granted to the skeletal muscle-specific drug therapy NMD670 Under this newly granted orphan drug designation, NMD670 is currently being evaluated in a Phase 2 ...